Osang Healthcare Co.,Ltd
Financials
Valuation Metrics
Osang Healthcare Co.,Ltd's Market Cap is ₩939B. At end of 2025 it was ₩1694B. Ranked #1277 of 2,436 in KR market (top 52%), #692 of 1,649 on KOSDAQ (top 42%), #49 of 96 in Health Care Equipment & Services (top 51%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 93.87B KRW | KR#1,277/2,436 Sec#49/96 |
| Revenue | 119.38B KRW | KR#1,301/2,436 Sec#23/96 |
| Net Income | -4.44B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 341.78B KRW | KR#937/2,436 Sec#18/96 |
| Net Assets | 281.66B KRW | KR#726/2,436 Sec#14/96 |
| Employees | 343 | KR#695/2,436 Sec#17/96 |
| Value | ||
| P/B | 0.33x | KR#393/2,436 Sec#5/96 |
| P/S | 0.79x | KR#1,229/2,436 Sec#18/96 |
| FCF Yield | -10.53% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -1.58% | KR#1,594/2,436 Sec#53/96 |
| ROA | -1.30% | KR#1,633/2,436 Sec#53/96 |
| Op. Margin | -5.05% | KR#1,864/2,436 Sec#56/96 |
| Revenue Growth | -28.80% | KR#2,160/2,436 Sec#83/96 |
| Earnings Growth | -191.31% | KR#1,490/2,436 Sec#49/96 |
| Financial Health | ||
| Debt Ratio | 121.34% | KR#686/2,436 Sec#31/96 |
| Total Debt | 46.95B KRW | KR#1,006/2,436 Sec#25/96 |
| FCF | -9.88B KRW | KR#1,710/2,436 Sec#62/96 |
| Cash | 17.46B KRW | KR#1,324/2,436 Sec#35/96 |
| Current Ratio | 2.59x | KR#719/2,436 Sec#40/96 |
| Dividend | ||
| Div. Yield | 3.21% | KR#623/2,436 Sec#7/96 |
| Div. Growth | -60.00% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | -62.30% | KR#2,264/2,436 Sec#86/96 |
| 1M Return | 12.14% | KR#232/2,436 Sec#16/96 |
| From 52W High | -66.19% | KR#2,001/2,436 Sec#72/96 |
| 1Y MDD | -76.41% | KR#2,201/2,436 Sec#87/96 |
| Trading | ||
| Volume | 10,352 shares | KR#2,105/2,436 Sec#87/96 |
| Foreign Own. | 1.94% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -305 KRW | KR—/2,436 Sec—/96 |
| BPS | 20,463 KRW | KR#503/2,436 Sec#7/96 |
Company Info
Established in 1996, Osang Healthcare develops, produces, and sells biochemical, immunoassay, and molecular diagnostic products in the in-vitro diagnostics field, and was listed on KOSDAQ in 2024. With the new consolidation of OSANG COSMETIC LTDA, a Brazilian cosmetic distribution company, in 2025, the company now holds three subsidiaries. Its product portfolio includes self-blood glucose meters and POCT HbA1c meters for biochemical diagnostics; SelexOn and COVID-19 self-test kits for immunoassay diagnostics; and PCR-based Genefinder products for molecular diagnostics. Osang Healthcare is headquartered in Anyang-si, Gyeonggi-do.